Navigation Links
Pressure BioSciences, Inc. Provides Corporate Update

SOUTH EASTON, Mass., Oct. 8 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today provided an update on various corporate activities, including the presentation of favorable data generated by scientists at Amgen, Inc. on the Company's pressure cycling technology ("PCT"), the scheduled presentation by Dr. Paul Pevsner of the NYU School of Medicine on the use of PCT in identifying potential protein biomarkers in colon cancer samples, and guidance relative to forecasted Q32008 and FY2008 sales of the Company's Barocycler instruments.

1) Amgen Presentation: data were presented by scientists from Amgen at the 35th meeting of the Federation of Analytical Chemistry and Spectroscopy Societies (FACSS) comparing PCT to their standard overnight procedure and the popular CEM, Inc. microwave-assisted technique for the digestion of a therapeutic monoclonal antibody. Amgen scientists reported that, "Pressure cycling was shown to be most effective at achieving complete digestion in a short time, without unintended perturbation of the molecule. Microwave digestion did not achieve complete digestion and induced oxidation of methionine residues." The authors concluded that, "PCT represents an increase in throughput and efficiency of at least 20-fold over the current conditions ... pressure cycling provided the most effective method for digesting monoclonal antibodies."

2) Dr. Paul Pevsner Presentation: Dr. Pevsner, Associate Professor of Pharmacology at the NYU School of Medicine, is scheduled to speak at the "Discovery2Diagnostics" Conference (San Diego, CA) on Monday, October 20th. Dr. Pevsner's talk, entitled "MALDI Imaging and Mass Spectrometry Identification of Colorectal Cancer Biomarkers", will include a discussion on the advantages of PCT versus other sample preparation methods available today. Dr. Pevsner is also expected to present data on the discovery of several proteins that he and his colleagues have found in colon cancer samples using PCT that have not been previously found in similar samples using other sample preparation techniques.

3) Guidance on Barocycler Sales: on August 14th, the Company announced that it expected to install at least fourteen (14) PCT Sample Preparation Systems during Q32008. The Company is pleased to announce that it has installed 17 PCT Systems, as compared to 7 in the second quarter of 2008. Furthermore, the Company expects to meet or exceed its previously announced full year guidance of 40 installations.

Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc., commented: "The continued publications and presentations from early adopters of PCT is helping us tremendously in our commercialization efforts. We attribute a significant portion of our recent commercial success to testimonials like the ones highlighted above, that herald the merits of pressure cycling technology in various applications of life sciences, as well as the advantages of PCT over other sample preparation methods available today. We would like to congratulate our customers and collaborators for their important research studies and for their continued support of PCT."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly-traded company focused on the development and commercialization of a novel, enabling technology called pressure cycling technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements include statements regarding data presented at the FACSS Meeting by scientists at Amgen; the expected presentation by Dr. Paul Pevsner at the upcoming Discovery2Diagnostics Conference; and expected installations of Barocycler instruments during Q32008 and expected installations during FY2008. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: the possibility that other scientists will be unable to reproduce the findings reported by scientists at Amgen that indicate that PCT provides a most effective method for digesting monoclonal antibodies; due to scientific and medical challenges, the possibility that the data generated by Dr. Pevsner and his colleagues to be presented at the October 2008 Discovery2Diagnostics Conference, may not be reproduced by other researchers in the future; that due to competitive products, services, and technological advances, PCT may not be the preferred method of sample preparation by other scientists and laboratories; the possibility that due to unforeseen issues, the Company may not install seventeen (17) PCT Systems in Q32008 and it may not meet or exceed (40) installations in FY2008; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
Visit us at our website .

Investor Contacts:

Richard T. Schumacher, President & CEO

Pressure BioSciences, Inc.

Edward H. Myles, Sr. Vice President of Finance & CFO

(508) 230-1828 (T)

SOURCE Pressure BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pressure Cycling Technology (PCT) Highlighted in Five Podium Presentations at the Fifth International Conference on High Pressure; PBI Introduces the Patent-pending PCT Shredder at the Meeting
2. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
3. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
4. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
5. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
6. Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics
7. Healthcare Industry Faces Mounting Pressure to Prevent On-The-Job Violence, Says Veteran Safety and Health Attorney
8. RADI Medical Systems Launches Next Generation PressureWire(R) Certus
9. Four Independent Research Groups Present Data Generated by Pressure Cycling Technology (PCT) at the ASMS Conference on Mass Spectrometry and Allied Topics in Denver, CO
10. InterCure Supports AHA Endorsement of Home Blood Pressure Monitoring
11. International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group announced the opening of a ... of Arica and Iquique in northern Chile. The facilities are part of GSCG’s expansion efforts ... protocols and techniques in stem cell medicine to patients from around the world. , The ...
(Date:11/30/2015)... , Nov. 30, 2015 Harvard ... ), a biotechnology company developing bioengineered organ implants ... written notification from The NASDAQ Stock Market that ... price requirements. The letter noted that as a ... common stock having exceeded $1.00 per share for ...
(Date:11/30/2015)... , Nov. 30, 2015 Human Longevity, Inc. ... company has acquired Cypher Genomics, Inc., a leading genome ... genomic interpretation software solutions. The San Diego ... HLI including Cypher CEO and Co-founder, Ashley Van Zeeland ... Pediatric Business.  Financial details of the deal were not ...
(Date:11/30/2015)... Germany , November 30, 2015 ... Vienna, Austria to be held December 1-4, 2015. ... in Vienna, Austria to be held ... subsidiary of Vycor Medical, Inc. ("Vycor") (OTCQB: VYCO), announced that ... Suite at the 3rd European Congress of NeuroRehabilitation (ECNR) ...
Breaking Biology Technology:
(Date:11/16/2015)... JOSE, Calif. , Nov 16, 2015 /PRNewswire/ ... developer of human interface solutions, today announced expansion ... Synaptics TouchView ™ touch controller and display ... architectural revolution of smartphones. These new TDDI products ... include TD4100 (HD resolution), TD4302 (WQHD resolution), and ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
Breaking Biology News(10 mins):